Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label study of olopatadine hydrochloride ophthalmic solution 0.2% in allergic conjunctivitis
2017-003953-41Phase 3
- Sponsor
- Alcon Inc.
- Start
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of olopatadine in allergic conjunctivitis (AC), sponsored by Alcon Inc. Primary endpoint: Mean Change from Baseline in Itching Score by Visit.
02
Drugs
olopatadine
03
Conditions
allergic conjunctivitis (AC)
Beyond the preview
Go deeper on 2017-003953-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003953-41.